These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 17922407)
1. A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication. Foli A; Maiocchi MA; Lisziewicz J; Lori F J Infect Dis; 2007 Nov; 196(9):1409-15. PubMed ID: 17922407 [TBL] [Abstract][Full Text] [Related]
2. The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients. Pogliaghi M; Papagno L; Lambert S; Calin R; Calvez V; Katlama C; Autran B AIDS; 2014 Jan; 28(2):278-81. PubMed ID: 24361684 [TBL] [Abstract][Full Text] [Related]
3. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. Schläpfer E; Fischer M; Ott P; Speck RF AIDS; 2003 Jul; 17(11):1613-20. PubMed ID: 12853743 [TBL] [Abstract][Full Text] [Related]
4. Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. Elahi S; Weiss RH; Merani S AIDS; 2016 Jan; 30(2):171-83. PubMed ID: 26645604 [TBL] [Abstract][Full Text] [Related]
5. Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription. Bermejo M; López-Huertas MR; Hedgpeth J; Mateos E; Rodríguez-Mora S; Maleno MJ; Plana M; Swindle J; Alcamí J; Coiras M Biochem Pharmacol; 2015 Apr; 94(4):241-56. PubMed ID: 25732195 [TBL] [Abstract][Full Text] [Related]
6. Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1. Heredia A; Davis C; Amoroso A; Dominique JK; Le N; Klingebiel E; Reardon E; Zella D; Redfield RR Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4179-84. PubMed ID: 12644703 [TBL] [Abstract][Full Text] [Related]
7. Potential role of immune modulation in the effective long-term control of HIV-1 infection. Rizzardi GP; Lazzarin A; Pantaleo G J Biol Regul Homeost Agents; 2002; 16(1):83-90. PubMed ID: 12003181 [TBL] [Abstract][Full Text] [Related]
8. Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells. Bermejo M; López-Huertas MR; García-Pérez J; Climent N; Descours B; Ambrosioni J; Mateos E; Rodríguez-Mora S; Rus-Bercial L; Benkirane M; Miró JM; Plana M; Alcamí J; Coiras M Biochem Pharmacol; 2016 Apr; 106():30-45. PubMed ID: 26851491 [TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea to inhibit human immunodeficiency virus-1 replication. Romanelli F; Pomeroy C; Smith KM Pharmacotherapy; 1999 Feb; 19(2):196-204. PubMed ID: 10030769 [TBL] [Abstract][Full Text] [Related]
11. New bis(thiosemicarbazonate) gold(III) complexes inhibit HIV replication at cytostatic concentrations: potential for incorporation into virostatic cocktails. Fonteh PN; Keter FK; Meyer D J Inorg Biochem; 2011 Sep; 105(9):1173-80. PubMed ID: 21708102 [TBL] [Abstract][Full Text] [Related]
12. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects]. Marcello A; Giacca M Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891 [No Abstract] [Full Text] [Related]
13. HIV-1 and HAART: a time to cure, a time to kill. Saag MS; Kilby JM Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490 [No Abstract] [Full Text] [Related]
14. Hydroxyproline-containing collagen peptide derived from the skin of the Alaska pollack inhibits HIV-1 infection. Jang IS; Park SJ Mol Med Rep; 2016 Dec; 14(6):5489-5494. PubMed ID: 27878297 [TBL] [Abstract][Full Text] [Related]
15. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Lori F; Lisziewicz J Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905 [TBL] [Abstract][Full Text] [Related]
16. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4. Cabrera C; Witvrouw M; Gutiérrez A; Clotet B; Kuipers ME; Swart PJ; Meijer DK; Desmyter J; De Clercq E; Esté JA AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1535-43. PubMed ID: 10580404 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. Aquaro S; Svicher V; Schols D; Pollicita M; Antinori A; Balzarini J; Perno CF J Leukoc Biol; 2006 Nov; 80(5):1103-10. PubMed ID: 16931601 [TBL] [Abstract][Full Text] [Related]
18. Cytokine regulation of HIV replication induced by dendritic cell-CD4-positive T cell interactions. Weissman D; Daucher J; Barker T; Adelsberger J; Baseler M; Fauci AS AIDS Res Hum Retroviruses; 1996 Jun; 12(9):759-67. PubMed ID: 8738427 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of human immunodeficiency virus type 1 replication by a bioavailable serine/threonine kinase inhibitor, fasudil hydrochloride. Sato T; Asamitsu K; Yang JP; Takahashi N; Tetsuka T; Yoneyama A; Kanagawa A; Okamoto T AIDS Res Hum Retroviruses; 1998 Mar; 14(4):293-8. PubMed ID: 9519889 [TBL] [Abstract][Full Text] [Related]
20. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Demonté D; Quivy V; Colette Y; Van Lint C Biochem Pharmacol; 2004 Sep; 68(6):1231-8. PubMed ID: 15313421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]